Giovanna Gattuso

Giovanna Gattuso

Auto-generated profile, based on publicly available information

Giovanna Gattuso

Pediatric Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
AFAndrea Ferrari
Andrea Ferrari
LBLuca Bergamaschi
Luca Bergamaschi
SCStefano Chiaravalli
Stefano Chiaravalli
VLVirginia Livellara
Virginia Livellara
GSGiovanna Sironi
Giovanna Sironi
MCMichela Casanova
Michela Casanova

28 December 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
VLVirginia Livellara
Virginia Livellara
LBLuca Bergamaschi
Luca Bergamaschi
NPNadia Puma
Nadia Puma
SCStefano Chiaravalli
Stefano Chiaravalli
MPMarta Podda
Marta Podda
AFAndrea Ferrari
Andrea Ferrari

Verified
Journal Article
Open access
PDF file
MKMarije Klumpers
Marije Klumpers
WWWard De Witte
Ward De Witte
GGGiovanna Gattuso
Giovanna Gattuso
ESElisabetta Schiavello
Elisabetta Schiavello
MTMonica Terenziani
Monica Terenziani
DLD. Maroeska W.M. te Loo
D. Maroeska W.M. te Loo
Nephrotoxicity is a common and dose-limiting side effect of platinum compounds, which often manifests as acute kidney injury or hypomagnesemia. This study aimed to investigate the genetic risk loci for platinum-induced nephrotoxicity. Platinum-treated brain tumor and head–neck tumor patients were genotyped with genome-wide coverage. The data regarding the patient and treatment characteristics and the laboratory results reflecting the nephrotoxicity during and after the platinum treatment were collected from the medical records. Linear and logistic regression analyses were performed to investigate the associations between the genetic variants and the acute kidney injury and hypomagnesemia phenotypes. A cohort of 195 platinum-treated patients was included, and 9,799,032 DNA variants passed the quality control. An association was identified between RBMS3 rs10663797 and acute kidney injury (coefficient −0.10 (95% confidence interval −0.13–−0.06), p-value 2.72 × 10−8). The patients who carried an AC deletion at this locus had statistically significantly lower glomerular filtration rates after platinum treatment. Previously reported associations, such as BACH2 rs4388268, could not be replicated in this study’s cohort. No statistically significant associations were identified for platinum-induced hypomagnesemia. The genetic variant in RBMS3 was not previously linked to nephrotoxicity or related traits. The validation of this study’s results in independent cohorts is needed to confirm this novel association.

28 January 2021 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
MSMatteo Silva
Matteo Silva
FBFrancesco Barretta
Francesco Barretta
RLRoberto Luksch
Roberto Luksch
MTMonica Terenziani
Monica Terenziani
MCMichela Casanova
Michela Casanova
AFAndrea Ferrari
Andrea Ferrari
Background: Cancer diagnosis and related treatment can limit young patients’ privacy. Their need for private physical and psychological spaces can be impeded by limited freedom, e.g., sharing hospital rooms with others and exposing their body to their parents and doctors. Methods: We conducted a survey among young patients of our center to investigate how their perception of privacy changed after being diagnosed with cancer and their need for hospital dedicated physical spaces and time for patients to enjoy their privacy. A questionnaire with 16 items was developed by the staff involving psychologists and physicians. The relevance of changes before and after the cancer diagnosis was assessed by calculating two scores indicating the situation before and after diagnosis for each answer, as well as a delta score. Results: Between May and June 2020, the questionnaire was completed by 60 patients aged 16–24 years. The median delta scores describing the changes before and after diagnosis were −8 points for perception of privacy, indicating a significant decrement of the level of privacy perceived. A major issue was the constant presence of parents being perceived as intrusive. Concerning hospital dedicated physical spaces and time for patients to enjoy their privacy, respondents requested dedicated spaces (50% of patients) and opportunities to have private interviews with medical personnel (88%). Conclusions: Our study offers a snapshot of how young people with cancer perceive the impact of the disease and its treatment on their privacy with the restrictions imposed on their individual freedom. Patients’ personal needs must be taken into consideration to adopt appropriate measures and better organize wards.

13 May 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
SCStefano Chiaravalli
Stefano Chiaravalli
LBLuca Bergamaschi
Luca Bergamaschi
VLVirginia Livellara
Virginia Livellara
GSGiovanna Sironi
Giovanna Sironi
NPNadia Puma
Nadia Puma
AFAndrea Ferrari
Andrea Ferrari

10 October 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
LBLuca Bergamaschi
Luca Bergamaschi
SCStefano Chiaravalli
Stefano Chiaravalli
VLVirginia Livellara
Virginia Livellara
GSGiovanna Sironi
Giovanna Sironi
NPNadia Puma
Nadia Puma
AFAndrea Ferrari
Andrea Ferrari
Background: Patients with relapsing rhabdomyosarcoma (RMS) pose a therapeutic challenge, and the survival rate is reportedly poor. We describe a retrospective series of relapsing RMS patients treated at a referral center for pediatric sarcoma, investigating the pattern of relapse, salvage rates, and factors correlating with final outcomes.Methods: The analysis concerned 105 patients <21 years old treated from 1985 to 2020 with initially localized RMS at first relapse. For risk‐adapted stratification purposes, patient outcomes were examined using univariable and multivariable analyses based on patients’ clinical features at first diagnosis, first‐line treatments, clinical findings at first relapse, and second‐line treatments.Results: First relapses occurred 0.08–4.8 years (median 1 year) following initial diagnosis and were local/locoregional in 59% of cases. Treatment at first relapse included chemotherapy in all but two cases, radiotherapy in 38, and surgery in 21. Median event‐free survival (EFS) after first relapse was 4 months, while 5‐year EFS was 16.3%; median overall survival (OS) was 9 months, while 5‐year OS was 16.7%. Several variables influenced survival rates. Considering only clinical findings and treatment at relapse, Cox's multivariable analysis showed that OS correlated significantly with time to relapse, radiotherapy administered at relapse, response to chemotherapy, and whether a second remission was achieved.Conclusion: Survival following first relapse of patients with localized RMS at initial diagnosis is poor. The variables found to influence survival can be utilized in a risk‐adapted model to estimate the chances of salvage to guide decisions for second‐line treatments.